World Journal of Surgery

, Volume 36, Issue 12, pp 2858–2864 | Cite as

Hyperfractionated Irradiation with 3 Cycles of Induction Chemotherapy in Stage IIIA-N2 Lung Cancer

  • Fengshi Chen
  • Kenichi Okubo
  • Makoto Sonobe
  • Keiko Shibuya
  • Yukinori Matsuo
  • Young Hak Kim
  • Kazuhiro Yanagihara
  • Toru Bando
  • Hiroshi Date
Article

Abstract

Background

The purpose of the present study was to improve the prognosis of patients with stage IIIA-N2 non-small cell lung cancer (NSCLC). To achieve that goal, we performed induction chemoradiotherapy followed by surgery.

Methods

The criteria for this phase II study were ≤75-year-old patients with pathologically diagnosed stage IIIA-N2 NSCLC who had performance statuses of 0 or 1 with good organ function. Three cycles of chemotherapy with paclitaxel and carboplatin were carried out, with concurrent hyperfractionated irradiation (42 Gy). After re-evaluation, pulmonary resections were considered unless patients showed progressive disease. The primary endpoint was overall survival (OS), and the secondary endpoints were disease-free survival (DFS) and absence of toxicity.

Results

All 22 patients enrolled in this study completed the induction chemoradiotherapy without any severe complications. In these 22 patients, the 2- and 5-year OS were 81 and 47 %, respectively. There were no therapy-related deaths. Surgery was subsequently performed in 19 patients (86 %). Pathological complete responses were seen in 6 patients (27 %), while node downstaging was obtained in 10 patients (45 %). In the 19 patients who underwent surgery, the 2- and 5-year OS rates were 83 and 62 %, respectively, and the 2-year DFS rate was 63 %. All 6 patients with pathological complete responses survived without disease. Patients with residual multiple-station N2 showed worse OS and DFS rates than did those with downstaged and single-station N2 (P = 0.026 and P < 0.0001, respectively).

Conclusions

This trimodal therapy was effective and well tolerated, and it is an acceptable therapeutic option for patients with locally advanced stage IIIA-N2 NSCLC. Patients without persistent multiple-station N2 showed promising survival.

References

  1. 1.
    Albain KS, Swann RS, Rusch VW et al (2009) Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomized controlled trial. Lancet 374:379–386PubMedCrossRefGoogle Scholar
  2. 2.
    Choi NC, Carey RW, Daly W et al (1997) Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small cell lung cancer. J Clin Oncol 15:712–722PubMedGoogle Scholar
  3. 3.
    Katakami N, Okazaki M, Nishiuchi S et al (1998) Induction chemoradiotherapy for advanced stage III non-small cell lung cancer: long-term follow-up in 42 patients. Lung Cancer 22:127–137PubMedCrossRefGoogle Scholar
  4. 4.
    Eberhardt W, Wilke H, Stamatis G et al (1998) Preoperative chemotherapy followed by concurrent chemoradiotherapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial. J Clin Oncol 16:622–634PubMedGoogle Scholar
  5. 5.
    Trodella L, Granone P, Valente S et al (2004) Neoadjuvant concurrent radiochemotherapy in locally advanced (IIIA–IIIB) non-small cell lung cancer: long-term results according to downstaging. Ann Oncol 15:389–398PubMedCrossRefGoogle Scholar
  6. 6.
    Pfister DG, Johnson DH, Azzoli CG et al (2004) American Society of Clinical Oncolgy. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22:330–353PubMedCrossRefGoogle Scholar
  7. 7.
    Sause W, Kolesar P, Taylor S IV et al (2000) Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117:358–364PubMedCrossRefGoogle Scholar
  8. 8.
    van Meerbeeck JP, Kramer GWPM, van Schil PEY et al (2007) Randomised controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 99:442–450PubMedCrossRefGoogle Scholar
  9. 9.
    Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216PubMedCrossRefGoogle Scholar
  10. 10.
    Mountain CF (1997) Revisions in the international system for staging lung cancer. Chest 111:1710–1717PubMedCrossRefGoogle Scholar
  11. 11.
    Farray D, Mirkovic N, Albain KS (2005) Multimodality therapy for stage III non-small cell lung cancer. J Clin Oncol 23:3257–3269PubMedCrossRefGoogle Scholar
  12. 12.
    Arriagada R, Dunant A, Bergman B et al (2004) The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N Engl J Med 350:351–360PubMedCrossRefGoogle Scholar
  13. 13.
    Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 311:899–909CrossRefGoogle Scholar
  14. 14.
    Winton T, Livingston R, Johnson D et al (2005) Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352:2589–2597PubMedCrossRefGoogle Scholar
  15. 15.
    Albain KS, Rusch VW, Crowley JJ et al (1995) Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 13:1880–1892PubMedGoogle Scholar
  16. 16.
    Belani CP, Lee JS, Socinski MA et al (2005) Randomized phase III trial comparing cisplatin–etoposide to carboplatin–paclitaxel in advanced or metastatic non-small cell lung cancer. Ann Oncol 16:1069–1075PubMedCrossRefGoogle Scholar
  17. 17.
    Machtay M, Lee JH, Stevenson JP et al (2004) Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response. J Thorac Cardiovasc Surg 127:108–113PubMedCrossRefGoogle Scholar
  18. 18.
    Girard N, Mornex F, Douillard JY et al (2010) Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial. Lung Cancer 69:86–93PubMedCrossRefGoogle Scholar
  19. 19.
    Friedel G, Budach W, Dippon J et al (2010) Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study. J Clin Oncol 28:942–948PubMedCrossRefGoogle Scholar
  20. 20.
    Yokomise H, Gotoh M, Okamoto T et al (2007) Induction chemoradiotherapy (carboplatin–taxane and concurrent 50-Gy radiation) for bulky cN2, N3 non-small cell lung cancer. J Thorac Cardiovasc Surg 133:1179–1185PubMedCrossRefGoogle Scholar
  21. 21.
    Macchiarini P, Chapelier AR, Monnet I et al (1994) Extended operations after induction therapy for stage IIIB (T4) non-small cell lung cancer. Ann Thorac Surg 57:966–973PubMedCrossRefGoogle Scholar
  22. 22.
    Weder W, Collaud S, Eberhardt WE et al (2010) Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage III non-small-cell lung cancer. J Thorac Cardiovasc Surg 139:1424–1430PubMedCrossRefGoogle Scholar
  23. 23.
    Okubo K, Kobayashi M, Morikawa H et al (2006) Easier node dissection after chemoradiotherapy for lung cancer with collagen insertion at mediastinoscopy. Jpn J Thorac Cardiovasc Surg 54:268–272PubMedCrossRefGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2012

Authors and Affiliations

  • Fengshi Chen
    • 1
  • Kenichi Okubo
    • 1
  • Makoto Sonobe
    • 1
  • Keiko Shibuya
    • 2
  • Yukinori Matsuo
    • 2
  • Young Hak Kim
    • 3
  • Kazuhiro Yanagihara
    • 4
  • Toru Bando
    • 1
  • Hiroshi Date
    • 1
  1. 1.Department of Thoracic SurgeryKyoto UniversityKyotoJapan
  2. 2.Department of Radiation Oncology and Image-Applied TherapyKyoto UniversityKyotoJapan
  3. 3.Department of Respiratory MedicineKyoto UniversityKyotoJapan
  4. 4.Outpatient Oncology UnitKyoto UniversityKyotoJapan

Personalised recommendations